List of Excipients in Branded Drug DEXTROSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	DEXTROSE	dextrose	0264-1510	WATER
B Braun Medical Inc	DEXTROSE	dextrose	0264-7387	WATER
B Braun Medical Inc	DEXTROSE	dextrose	0264-7510	WATER

Generic Drugs Containing DEXTROSE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	dextrose monohydrate	65219-238	WATER
BECTON DICKINSON AND COMPANY	dextrose monohydrate and sodium chloride	17271-734	WATER
BECTON DICKINSON AND COMPANY	dextrose monohydrate and sodium chloride	17271-735	WATER

What are the Most Frequently-Used Excipients in DEXTROSE?

# Of NDCs	Excipient
1	WATER

Dextrose Excipient Strategy and Commercial Opportunities in Pharmaceutical Formulation

Last updated: September 5, 2026

Dextrose is a low-cost, globally available carbohydrate with limited composition-of-matter patent protection but significant formulation and supply-chain value. Commercial opportunities center on pharmaceutical-grade quality, parenteral nutrition, biologic stabilization, lyophilized products, ready-to-use presentations, and specialized delivery systems. The strongest defensible positions are usually based on formulation performance, impurity control, packaging, manufacturing, and device integration rather than dextrose itself.

What is dextrose used for in pharmaceutical products?

Dextrose is D-glucose. It is used as both an active pharmaceutical ingredient and an excipient, depending on the product.

Pharmaceutical role	Typical function	Representative products
Active ingredient	Raises blood glucose and supplies carbohydrate calories	Dextrose injection, oral glucose products
Tonicity agent	Adjusts osmolality	Parenteral solutions, ophthalmic products
Stabilizer	Protects proteins, enzymes, vaccines, and cells during processing or storage	Biologics and lyophilized products
Bulking agent	Adds solid mass to a lyophilized cake	Injectable biologics and diagnostic products
Cryoprotectant	Reduces freeze-concentration and ice-related damage	Cell and biologic formulations
Carbohydrate source	Provides metabolic energy	Parenteral nutrition and clinical nutrition
Processing aid	Supports granulation, drying, and powder formation	Oral solid dosage forms

Dextrose is commonly supplied as dextrose monohydrate or anhydrous dextrose. The hydrate state affects molecular weight, water content, stability, formulation calculations, and final product osmolality. Pharmaceutical developers must specify the form rather than treating all dextrose grades as interchangeable.

What are the main pharmaceutical forms of dextrose?

Dextrose is commercially available in several dosage-form and grade configurations.

Dextrose injection

Dextrose injection is supplied in aqueous intravenous solutions at concentrations that commonly include 5%, 10%, 20%, and 50%. Lower concentrations are used for fluid and carbohydrate administration, while higher concentrations are used when a concentrated glucose source is needed. High-concentration products are generally administered through appropriate venous access because of their high osmolarity.

A representative 5% dextrose injection contains 5 g of dextrose per 100 mL and supplies approximately 170 kilocalories per liter. The final pH, osmolarity, container, and administration instructions depend on the approved product and manufacturer. FDA labeling identifies hyperglycemia, fluid imbalance, electrolyte disturbance, and extravasation-related injury as key risks for parenteral dextrose products (FDA, 2023a).

Dextrose in parenteral nutrition

Dextrose is a principal energy source in total parenteral nutrition and peripheral parenteral nutrition. Commercial value comes from accurate concentration control, low endotoxin levels, container compatibility, and integration with amino acids, lipids, electrolytes, vitamins, and trace elements.

Dextrose solutions may be supplied in:

• Single-chamber bags
• Multi-chamber parenteral nutrition bags
• Pharmacy bulk packages
• Flexible infusion containers
• Concentrated containers for pharmacy compounding

Oral and solid dosage forms

Dextrose is used in glucose tablets, powders, oral rehydration products, chewable products, lozenges, and nutritional supplements. These products compete primarily on taste, dissolution, tablet robustness, packaging, regulatory claims, and distribution rather than on active-ingredient exclusivity.

Biologic and injectable excipient use

Dextrose can act as a stabilizer, bulking agent, or cryoprotectant in protein and cell-based products. Its suitability depends on the active molecule, concentration, pH, buffer system, storage temperature, and manufacturing process. Dextrose can participate in reducing-sugar chemistry, including Maillard-type reactions with amino groups, which limits its use in some protein formulations.

What excipient strategy should pharmaceutical companies use for dextrose?

The appropriate strategy depends on whether dextrose is the therapeutic agent, a formulation excipient, or a process material.

Use compendial, pharmaceutical-grade material for regulated products

For injectable products, the target specification should normally include:

• USP/NF or applicable pharmacopoeial compliance
• Identity and assay
• Water content
• Related substances and degradation products
• Endotoxin
• Bioburden
• Particulate matter
• Color and clarity
• Elemental impurities
• Residual solvents, where applicable
• Container-closure compatibility

The manufacturer should maintain separate controls for dextrose monohydrate and anhydrous dextrose. Substitution between the two forms can affect concentration calculations and finished-product specifications.

Control reducing-sugar reactivity

Dextrose is a reducing sugar. In formulations containing proteins, amino acids, peptides, or amine-containing drugs, the development program should assess:

• Loss of active potency
• New peaks in chromatographic assays
• Color formation
• Visible and subvisible particles
• pH drift
• Storage-temperature sensitivity
• Interaction with amino-acid components
• Compatibility with terminal sterilization

The risk is particularly relevant to combined dextrose-amino-acid nutrition products and biologic formulations containing primary or secondary amines.

Select concentration according to route and product objective

Concentration affects osmolality, venous tolerability, administration rate, package volume, and caloric delivery. A low-concentration solution may support peripheral administration, while a concentrated solution can reduce infusion volume but create greater vascular and tissue risk.

Product teams should avoid treating concentration as a simple cost decision. A higher concentration can improve logistics and reduce container count, but it may require central venous administration, different labeling, and more restrictive clinical use.

Match the container to the formulation

Dextrose solutions are commonly packaged in glass, plastic bottles, flexible bags, and pharmacy-compatible containers. The selection affects:

• Extractables and leachables
• Oxygen and moisture transmission
• Light protection
• Seal integrity
• Cold-storage performance
• Port configuration
• Shipping durability
• Compatibility with automated compounding systems

Flexible multilayer bags can reduce breakage and improve hospital handling. Their commercial differentiation is based on material construction, port design, usability, and stability rather than on the dextrose molecule.

What FDA regulatory status applies to dextrose products?

Dextrose has several regulatory positions depending on its use.

FDA-approved drug products

Dextrose injection products are approved drug products regulated under the Federal Food, Drug, and Cosmetic Act. FDA-approved labeling covers indications, concentration, route of administration, warnings, storage, and container information. The regulatory pathway for a new dextrose injection is generally an abbreviated or hybrid product strategy when a suitable reference product and dosage form exist, subject to the applicable FDA requirements.

Dextrose as an excipient

When dextrose is used as an inactive ingredient, its regulatory acceptability is product-specific. FDA’s Inactive Ingredient Database provides precedent for inactive ingredients in approved drug products, including route and dosage-form information (FDA, 2024a). A developer must evaluate whether the proposed concentration and route fall within established precedent.

Food and nutritional products

Dextrose used in foods, beverages, and dietary products follows a different regulatory framework from injectable pharmaceutical use. Food-grade status does not establish suitability for parenteral administration. Injectable products require pharmaceutical manufacturing controls and appropriate sterility and endotoxin controls.

What is the Orange Book status of dextrose?

The Orange Book status is product-specific, not molecule-wide. Dextrose as an old, simple carbohydrate does not have meaningful new-molecular-entity exclusivity. Approved dextrose injections may appear in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations depending on the specific product, dosage form, strength, and reference-product history (FDA, 2024b).

The principal commercial implications are:

Exclusivity category	Relevance to dextrose
New chemical entity exclusivity	Generally not relevant
Orphan-drug exclusivity	Not inherent to dextrose
Pediatric exclusivity	Product-specific
New clinical investigation exclusivity	Possible only if statutory requirements are met
Composition-of-matter patent	Commercially immaterial for dextrose
Formulation patent	Possible, but generally narrow
Container or device patent	Possible and potentially valuable
Method-of-use patent	Possible for a defined clinical use, but difficult to sustain for basic glucose administration

Dextrose products usually compete through manufacturing reliability, hospital contracts, shortages management, packaging, and cost rather than through long-term exclusivity.

What patents protect dextrose pharmaceutical products?

No broad, commercially meaningful patent estate protects dextrose itself as a chemical substance. Dextrose has been known and used for decades, making new composition-of-matter protection unavailable in ordinary circumstances.

Patentable subject matter may exist in four areas.

Formulation patents

A formulation patent may cover a defined combination of dextrose with:

• A biologic or peptide
• A buffer
• An antioxidant
• An amino acid
• A surfactant
• A cryoprotectant
• A preservative system
• A specific pH range
• A concentration or ratio
• A defined stability profile

The patent must distinguish the claimed formulation from routine selection of dextrose as a carbohydrate, bulking agent, or tonicity modifier. Claims based only on using dextrose in a conventional role are vulnerable to anticipation or obviousness challenges.

Manufacturing patents

Manufacturing claims may address:

• Low-endotoxin purification
• Crystallization control
• Particle-size engineering
• Anhydrous conversion
• Sterile filtration
• Aseptic filling
• Lyophilization cycles
• Continuous manufacturing
• Removal of trace impurities
• Prevention of discoloration or degradation

Manufacturing patents are more valuable when the process produces a measurable product attribute that competitors cannot easily reproduce.

Container and delivery patents

Commercially relevant claims may cover:

• Multi-chamber bags
• Ready-to-administer infusion systems
• Pharmacy compounding interfaces
• Dual-port containers
• High-concentration dextrose delivery devices
• Anti-free-flow systems
• Automated dosing or infusion controls
• Light-protective packaging
• Low-sorption container materials

These rights may create practical barriers even when the dextrose solution itself is unpatented.

Method-of-use patents

A method-of-use patent could cover dextrose in a defined clinical context, such as a particular rescue protocol, infusion sequence, or combination with another therapy. Such patents face a high risk of narrow claim scope because glucose administration is established medical practice.

How strong is the patent estate for dextrose?

The dextrose molecule has a weak patent estate. Product-level protection can be moderate when it combines formulation, manufacturing, and device claims.

Protection layer	Typical strength	Main vulnerability
Dextrose composition	Very low	Long-known substance
Standard aqueous injection	Low	Routine formulation and established use
Specialized biologic formulation	Moderate	Prior-art combinations and obviousness
Multi-chamber nutrition system	Moderate to strong	Design-around and device substitution
Low-endotoxin manufacturing process	Moderate	Process replication and claim narrowness
Proprietary container closure	Moderate	Alternative packaging configurations
Clinical method of use	Low to moderate	Established medical practice and narrow indication

Trade secrets can be more durable than patents for purification parameters, crystallization conditions, filling controls, supplier qualification, and stability data. Trade-secret value is highest when the process improves particulate control, endotoxin performance, shelf life, or manufacturing yield.

What commercial opportunities exist for dextrose excipients?

High-purity dextrose for biologics

Biologic developers need excipients with consistent impurity profiles and reliable global supply. Suppliers can differentiate through:

• Tighter endotoxin specifications
• Low bioburden grades
• Consistent hydrate state
• Trace-metal control
• Low color
• Lot-to-lot uniformity
• Regulatory documentation
• Multi-site supply qualification

The commercial opportunity is strongest when dextrose is used in an injectable or lyophilized biologic where a supplier change can trigger comparability and stability work.

Ready-to-use parenteral nutrition

Hospitals and compounding pharmacies value products that reduce manipulation and contamination risk. Dextrose-containing ready-to-use and multi-chamber nutrition bags can compete on:

• Reduced compounding labor
• Lower preparation error rates
• Shelf life
• Cold-chain requirements
• Compatibility with standard infusion equipment
• Pediatric and adult dosing flexibility

Specialty concentrations and pediatric products

Pediatric, neonatal, and critical-care applications require concentration flexibility and accurate low-volume administration. Commercial differentiation can come from small-volume containers, calibrated presentations, dose-band support, and compatibility with infusion pumps.

Lyophilized biologics and vaccines

Dextrose can be evaluated as a low-cost alternative or complement to established stabilizers. The opportunity depends on demonstrating superior cake structure, reconstitution time, recovery, and storage stability without increasing aggregation or chemical degradation.

Oral glucose delivery

Oral glucose products have room for differentiation through rapid dissolution, taste masking, portability, diabetic-use positioning, and packaging designed for emergency access. Patent value is likely to reside in dosage-form engineering, flavor systems, or packaging rather than in dextrose.

Pharmaceutical-grade supply security

Dextrose is a high-volume, low-margin material. The strongest supplier opportunity is often supply assurance. Customers may pay for validated alternate sites, strategic inventory, shorter lead times, and documented change-control practices when dextrose is used in critical injectable products.

Which companies and manufacturers compete in dextrose pharmaceuticals?

Competition exists across several segments:

Segment	Representative competitive groups
Dextrose injections	Large hospital injectable manufacturers and generic parenteral companies
Parenteral nutrition	Baxter, Fresenius Kabi, B. Braun and other nutrition suppliers
Pharmaceutical excipient supply	Global carbohydrate and excipient manufacturers
Oral glucose products	Consumer-health, nutrition, and generic-drug companies
Packaging and delivery	Infusion-container, medical-device, and compounding-system suppliers

The competitive field changes by country, hospital contract, shortage status, and approved concentration. Supplier qualification and manufacturing continuity often matter more than brand identity.

What generic entry risks exist for dextrose products?

Generic-entry risk is high for standard dextrose injections because:

• The active ingredient is old and well characterized.
• Conventional aqueous formulations are technically straightforward.
• Clinical use is established.
• Multiple suppliers can manufacture comparable concentrations.
• Patent barriers are limited.
• Substitution may occur through hospital purchasing systems.

Risk is lower for products that combine dextrose with complex nutrition systems, specialized containers, proprietary administration devices, or difficult-to-reproduce stability attributes. Even in those categories, a competitor may enter through a different package or formulation design.

Paragraph IV challenges

A Paragraph IV certification is relevant only when an abbreviated applicant challenges a listed patent for a specific reference product. Because dextrose itself lacks meaningful foundational patent protection, Paragraph IV exposure is generally tied to product-level formulation, packaging, or use patents. A challenge could seek a declaration that a listed patent is invalid, unenforceable, or not infringed.

The commercial value of such patents depends on whether the listing covers the product actually purchased by hospitals. A narrow container or formulation claim may have limited impact if a rival can launch a non-infringing alternative.

What patent litigation and settlement issues affect dextrose?

Dextrose has limited molecule-level litigation exposure. Disputes are more likely to concern:

• Formulation patents for combination products
• Nutrition bag architecture
• Infusion-device claims
• Manufacturing processes
• Trade-secret misappropriation
• Regulatory exclusivity for a particular approved product
• Supply contracts and shortage-related procurement

Settlement agreements involving ordinary dextrose injections are less likely to produce the market-shaping outcomes seen in complex small molecules. The relevant diligence question is whether a dispute blocks the product presentation that hospitals actually use, not whether it covers dextrose generally.

How does dextrose compare with other pharmaceutical carbohydrates?

Attribute	Dextrose	Sucrose	Mannitol	Trehalose
Reducing sugar	Yes	No	No	No
Common parenteral use	High	Moderate	Moderate	Moderate
Protein-stability use	Product-dependent	Common	Common	Common
Maillard-reaction risk	Higher	Lower	Lower	Lower
Cost and availability	Very favorable	Favorable	Higher	Higher
Caloric contribution	Yes	Yes	Limited metabolic use	Yes
Main advantage	Low cost and metabolic utility	Stability and low reactivity	Tonicity and bulking	Biologic stabilization
Main limitation	Chemical reactivity and hyperglycemia	Hydrolysis and formulation dependence	Hemodynamic and renal considerations	Cost and supply qualification

Dextrose is strongest where carbohydrate calories, tonicity, or low cost matter. It is less attractive where non-reducing behavior and protein compatibility are the primary requirements.

What is the revenue exposure from dextrose products?

Revenue exposure is generally concentrated in volume-driven products rather than premium-priced medicines. Key commercial variables include:

• Hospital contract share
• Number of approved concentrations
• Container size
• Supply reliability
• Manufacturing utilization
• Parenteral nutrition penetration
• Shortage conditions
• Commodity dextrose costs
• Sterile-filling capacity
• Geographic registration coverage

A manufacturer with a broad dextrose portfolio can gain operating leverage from shared raw materials, filling lines, quality systems, and distribution. The margin profile is usually better for specialized bags, nutrition systems, and device-integrated products than for standard 5% dextrose injection.

What geographic coverage matters for dextrose?

Dextrose demand is global, but regulatory and commercial requirements differ.

United States

Key issues include FDA drug approval, current good manufacturing practice compliance, sterile manufacturing, drug-shortage reporting, approved labeling, and Orange Book status where applicable.

European Union

Products may require national or centralized authorization depending on the product category. Pharmacopoeial compliance, GMP, packaging requirements, and market-specific reimbursement influence launch economics.

Emerging markets

Demand is supported by hospital infrastructure expansion and parenteral nutrition use. Commercial risks include local registration timelines, tender pricing, local manufacturing requirements, currency volatility, and cold-chain limitations.

A dual-source strategy is commercially valuable because sterile dextrose products are vulnerable to manufacturing interruptions and container shortages.

Key Takeaways

1. Dextrose has little meaningful composition-of-matter patent protection.
2. The main commercial opportunities are parenteral nutrition, injectable supply, biologic stabilization, lyophilization, and specialized packaging.
3. Formulation patents must show a technical advantage over routine use of dextrose.
4. Manufacturing, container, and delivery-system patents can provide stronger practical protection than standard formulation claims.
5. FDA status, Orange Book listings, and Paragraph IV risk are product-specific.
6. Generic-entry risk is high for conventional dextrose injections and lower for complex nutrition systems and device-integrated products.
7. Pharmaceutical-grade supply assurance, low endotoxin, impurity control, and global redundancy are important commercial differentiators.
8. Dextrose is economically attractive when low cost and metabolic energy are priorities, but its reducing-sugar chemistry can limit use in protein and amino-acid formulations.

FAQs

Is dextrose a patented pharmaceutical ingredient?

No broad, commercially meaningful patent protection generally covers dextrose itself. Protection may apply to a particular formulation, manufacturing process, container, or delivery system.

Can dextrose be used in biologic drug formulations?

Yes. Dextrose can function as a stabilizer, bulking agent, or cryoprotectant, but developers must evaluate reducing-sugar reactions, protein aggregation, pH stability, and storage performance.

Is dextrose monohydrate interchangeable with anhydrous dextrose?

No. The hydrate state affects molecular weight, water content, formulation calculations, and finished-product properties. Any substitution requires formulation and quality assessment.

Are dextrose injections subject to generic competition?

Yes. Standard dextrose injections generally face high generic and contract-manufacturing competition because the active ingredient and conventional formulations are well established.

What is the most defensible commercial position in the dextrose market?

A validated platform combining pharmaceutical-grade raw material, sterile manufacturing, low-endotoxin control, reliable supply, specialized containers, and hospital-ready delivery systems is generally more defensible than an ordinary dextrose formulation.

References

1. U.S. Food and Drug Administration. (2023a). Dextrose injection prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. United States Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary: Dextrose monograph. Rockville, MD: United States Pharmacopeial Convention.

5. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.

6. International Council for Harmonisation. (2005). Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products. ICH.